Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by waves1on Oct 25, 2022 2:13pm

131 Views

Post# 35047432

AGN & Yale collab on clinical trial for DMT & Depression

AGN has entered a Clinical Trial Agreement with Yale University for the investigation of multiple intravenous doses of DMT for the treatment of depression!

The study will be developed cooperatively, with the intellectual property around the clinical use of DMT from the study being jointly owned by AGN.

Plus, the data which AGN will be receiving from the study may additionally assist in AGN's DMT stroke research program.

This is a significant opportunity as AGN currently has patents pending on novel forms of DMT which could be used across a broad range of diseases.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season